Rhythm Pharmaceuticals' 84% year-over-year revenue growth and 39% analyst upside target reflect a high-conviction commercial ramp for setmelanotide, but single-product concentration and below-floor quality scores make this a speculative position requiring close monitoring.
Thesis pillars
- Setmelanotide Revenue Ramp→Stable
- Momentum Surge Signal↑Improving
- Analyst Conviction Asymmetry↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 26, 2026· older than 90 days
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $110.68: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 16%; Below-average business quality; Rich valuation.
Rhythm Pharmaceuticals markets IMCIVREE (setmelanotide) for rare MC4R pathway diseases including BBS and POMC/PCSK1/LEPR deficiencies, with approvals in the US, EU, UK, and Canada. Revenue comes from specialty drug sales across more than 25 countries; cumulative product revenue... Read more
Sell if holding. Engine safety override at $110.68: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 16%; Below-average business quality; Rich valuation. Chart setup: Death cross but MACD improving, RSI 74. Score 5.4/10, moderate confidence.
Passes 4/8 gates (positive momentum, earnings proximity 111d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About Rhythm Pharmaceuticals, Inc.
About Rhythm Pharmaceuticals, Inc.
IMCIVREE (setmelanotide) became the first therapy approved for BBS and POMC/PCSK1/LEPR deficiency obesity when the FDA cleared it in 2020; Rhythm Pharmaceuticals has since secured authorization across more than 25 countries, generating approximately $422.5 million in cumulative product revenue through December 31, 2025. The company employed 414 people at February 1, 2026, and held $388.9 million in cash and short-term investments at year-end. An FDA decision on IMCIVREE for acquired hypothalamic obesity carried a PDUFA goal date of March 20, 2026.
Rhythm generates revenue from IMCIVREE sales through specialty pharmacy channels for an estimated 4,600 to 7,500 US patients in currently approved indications. The revenue interest financing agreement with HealthCare Royalty Management — fully drawn to $99.4 million net of issuance costs by September 2023 — carries tiered royalties of 11.5% on annual revenues up to $125 million, 7.5% between $125 million and $300 million, and 2.5% above $300 million, creating a persistent cash drag on gross receipts. Bivamelagon, licensed from LGC in January 2024, adds a low- to mid-single-digit royalty obligation on MC4R portfolio revenues starting in 2029. The company targets commercial expansion in Japan pending approval, with a new drug application planned following Phase 3 topline data from a 12-patient Japanese cohort expected in March 2026.
Show full overview
EMANATE, the Phase 3 basket trial testing setmelanotide across four genetically defined MC4R pathway diseases — heterozygous POMC/PCSK1 obesity, heterozygous LEPR obesity, SRC1 deficiency, and SH2B1 deficiency — was expected to deliver independent topline results from each substudy in March 2026. Each substudy is designed to support a separate NDA filing; an adverse safety finding in one cohort could trigger a clinical hold across the entire trial, exposing all four programs simultaneously. Bivamelagon completed a positive end-of-Phase-2 FDA meeting on February 26, 2026, partially diversifying the binary readout risk.
See also: Healthcare · Biotechnology
From Rhythm Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Rhythm Pharmaceuticals, Inc.
Latest news
- NEWS Rhythm Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 21.67% — benzinga Nov 4, 2026 positive
- NEWS 'AstraZeneca Made $10 Billion Offer For Rhythm Pharmaceuticals; Rhythm Specializes In Treatments For Metabolic Condition — benzinga Nov 4, 2026 positive
- NEWS NICE Issues Positive Guidance for IMCIVREE in Adults with Bardet-Biedl Syndrome — fiscal.ai Nov 4, 2026 neutral
- NEWS Rhythm Pharmaceuticals Announces Positive Phase 2 Results for Bivamelagon — fiscal.ai Nov 4, 2026 positive
- NEWS Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $166 — benzinga Nov 4, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:54:13Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductsetmelanotide10-K Item 1A: 'we have focused substantially all our efforts and financial resources on the research and development of setmelanotide'
Material Events(8-K, last 90d)
- 2026-04-03Item 5.02LOWKimberly J. Popovits elected as Class II non-employee director effective April 1, 2026, serving through 2028 annual meeting. Edward T. Mathers resigned from the Board effective April 1, 2026; no disagreement with company operations or practices cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $110.68: Quality below floor (3.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 16%; Below-average business quality; Rich valuation. Chart setup: Death cross but MACD improving, RSI 74. Prior stop was $102.93. Score 5.4/10, moderate confidence.
Analyst target: $126.26 (+14.1% upside). Prior stop was $102.93. Stop-loss: $102.93.
Concentration risk — Product: setmelanotide; Quality below floor (3.6 < 4.0); Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (6 sells, 3.23% of cap).
Rhythm Pharmaceuticals, Inc. trades at a P/E of N/A (forward -170.1). TrendMatrix value score: 3.6/10. Verdict: Sell.
24 analysts rate RYTM, with a consensus score of 4.3/5. 17 analysts publish price targets averaging $140.
What does Rhythm Pharmaceuticals, Inc. do?Rhythm Pharmaceuticals markets IMCIVREE (setmelanotide) for rare MC4R pathway diseases including BBS and...
Rhythm Pharmaceuticals markets IMCIVREE (setmelanotide) for rare MC4R pathway diseases including BBS and POMC/PCSK1/LEPR deficiencies, with approvals in the US, EU, UK, and Canada. Revenue comes from specialty drug sales across more than 25 countries; cumulative product revenue reached approximately $422.5 million through December 31, 2025.